Trial record 2 of 10 for: piemonti

Previous Study | Return to List | Next Study

Monotherapy With Rapamycin in Long-standing Type 1 Diabetes (MONORAPA)

This study is currently recruiting participants.

See

Contacts and Locations

Verified June 2016 by Piemonti Lorenzo, Ospedale San Raffaele

Sponsor:

Collaborator:

Fondazione Italiana Diabete Onlus

Information provided by (Responsible Party):

Piemonti Lorenzo, Ospedale San Raffaele

ClinicalTrials.gov Identifier:

NCT02803892

First received: June 10, 2016

Last updated: June 14, 2016

Last verified: June 2016

History of Changes

Purpose

This study is a phase 2, single-center, prospective, randomized, double-blind, placebo-controlled, 3-arm parallel group (1:1:1) intervention trial to determine the efficacy of 4 weeks rapamycin treatment and 4 weeks rapamycin treatment plus 3 months vildagliptin treatment versus placebo in increasing endogenous insulin production and correcting glycemic lability. It will involve 60 patients with long standing type 1 diabetes (T1D). Patients will receive for one month placebo (Group 1), rapamycin plus placebo (Group 2), or rapamycin plus Vildagliptin (Group 3). Rapamycin will be administered at an initial dose 0.2 mg/kg orally on day 0 followed by 0.1 mg/kg/die (target trough levels: 8-10 ng/ml). Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0. After 4 weeks of treatment (period A), patients will discontinue rapamycin or relevant placebo treatment, but continue Vildagliptin or placebo for a further 8 weeks and be monitored over this period (period B).

Condition	Intervention	Phase
Diabetes Mellitus, Type 1	Drug: rapamycin Drug: Vildagliptin Drug: Placebo 1 Drug: Placebo 2	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider) Primary Purpose: Treatment
Official Title:	Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study

Resource links provided by NLM:

Genetics Home Reference related topics: type 1 diabetes

MedlinePlus related topics: Diabetes Type 1

Drug Information available for: Sirolimus Everolimus Temsirolimus

U.S. FDA Resources

Further study details as provided by Piemonti Lorenzo, Ospedale San Raffaele:

Primary Outcome Measures:

Change from Baseline C-peptide response in the MMTT [ Time Frame: week 4±1, week 12±2 ]
the proportion of participants with a positive response to the MMTT defined as C-peptide at 90 min >0.6 ng/ml.
Change from Baseline C-peptide after the MMTT [ Time Frame: week 4±1, week 12±2 ]
change in the area under the curve of C-peptide after the MMTT vs baseline

Secondary Outcome Measures:

Change from Baseline insulin requirement [ Time Frame: week 4±1, week 12±2 ]
change in insulin requirement vs baseline
Change from Baseline fasting C-peptide [ Time Frame: week 4±1, week 12±2 ]
change in fasting C-peptide vs baseline
Change from Baseline HbA1c [ Time Frame: week 4±1, week 12±2 ]
change in HbA1c vs baseline
Adverse Events (AEs) related to the immunosuppression [ Time Frame: week 4±1, week 12±2 ]
the incidence and severity of Adverse Events (AEs) related to the immunosuppressive treatment
Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: week 4±1, week 12±2 ]
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)


Estimated Enrollment:	60
Study Start Date:	May 2016
Estimated Study Completion Date:	December 2018
Estimated Primary Completion Date:	May 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Group 1: Placebo Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks	Drug: Placebo 1 Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1 Drug: Placebo 2 Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
Experimental: Group 2: Rapamycin plus Placebo Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks	Drug: rapamycin Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL Other Name: Rapamune® Drug: Vildagliptin Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0. Other Name: GALVUS
Experimental: Group 3: Rapamycin plus Vildagliptin Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks	Drug: rapamycin Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL Other Name: Rapamune® Drug: Vildagliptin Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0. Other Name: GALVUS

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female aged >18 years, inclusive
Clinical history compatible with T1D with onset of disease at < 40 years of age, insulin dependence for ≥ 5 years at the time of enrolment
C-peptide concentrations under the threshold of preserved beta cell function: fasting C peptide <0.23 ng/ml
Detectable fasting proinsulin concentrations (>0.5 pmol/l)
Ability to provide written informed consent
Mentally stable and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations

Exclusion Criteria:

Body mass index (BMI) >30 kg/m2 or patient with body weight ≤40kg;
Insulin requirement >1.0 IU/kg/day or <10 U/day;
HbA1c >11% (normal value: 3.5-6.0%) at the time of enrolment
estimated glomerular filtration rate <60 mL/min/1.73m2 calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease [MDRD] study estimation formula)
Presence or history of macroalbuminuria (>300mg/g creatinine)
For female subjects: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation of treatment
Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB) as determined by a positive skin test or clinical presentation, or under treatment for suspected TB
Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin
Lymphopenia (<1,000/μL), neutropenia (<1,500/μL), or thrombocytopenia (platelets <100,000/μL).
Severe unremitting diarrhea, vomiting or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications
Any medical condition that will interfere with safe participation in the trial;
Any immunosuppressive treatment at the time of enrollment.
Allergy to active ingredients or to any of excipients

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02803892

Contacts


Contact: Lorenzo Piemonti, MD	0226432706 ext +39	piemonti.lorenzo@hsr.it
Contact: Andrea Bolla, MD	0226432822 ext +39	andrea.bolla@hsr.it

Locations


Italy
IRCCS San Raffaele Scientific Institute	Recruiting
Milan, Italy, 20132
Contact: Lorenzo Piemonti, MD piemonti.lorenzo@hsr.it
Contact: Andrea Bolla, MD andrea.bolla@hsr.it
Principal Investigator: Andrea Bolla, MD
Principal Investigator: Lorenzo Piemonti, MD
Principal Investigator: Emanuele Bosi, MD

Sponsors and Collaborators

Piemonti Lorenzo

Fondazione Italiana Diabete Onlus

Investigators


Principal Investigator:	Lorenzo Piemonti, MD	Ospedale San Raffaele
Study Chair:	Emanuele Bosi, MD	Ospedale San Raffaele

More Information


Responsible Party:	Piemonti Lorenzo, Deputy director San Raffaele Diabetes Research Institute (SR-DRI), Ospedale San Raffaele
ClinicalTrials.gov Identifier:	NCT02803892 History of Changes
Other Study ID Numbers:	DRI-2/2014 MONORAPA
Study First Received:	June 10, 2016
Last Updated:	June 14, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Sirolimus Everolimus Vildagliptin Dipeptidyl-Peptidase IV Inhibitors Anti-Bacterial Agents	Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Hypoglycemic Agents

ClinicalTrials.gov processed this record on July 21, 2017

To Top